Novartis, Daiichi to end OTC medicine contract in December

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Novartis Pharma kk and Sankyo Co., Ltd. have agreed to terminate their January 2004 agreement for the sale of Lamisil and the development of Nicotinell TTS at the end of December.

Novartis, a Basel, Switzerland-based pharmaceutical company, said it will sell Lamisil as its own product beginning in January and will solely develop Nicotinell TTS as an over-the-counter medicine.

Lamisil is currently sold by Daiichi Sankyo, a Tokyo-based pharmaceutical company and an affiliate of Daiichi Sankyo Co., Ltd.

The Novartis and Daiichi Sankyo contract of January 2004 stated that Daiichi Sankyo would sell the athlete's foot treatment products Lamisil AT Cream, Lamisil AT Solution and Lamisil AT Spray as over-the-counter medicine and that both companies would work in the co-development of the prescription-only smoking cessation medicine Nicotinell TTS as an over-the-counter medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.